The NIH Has the Opportunity to Address Research Funding Disparities
As the NIH prepares for a massive influx of funding, it must follow through on its commitment to address health research funding disparities.

As the NIH prepares for a massive influx of funding, it must follow through on its commitment to address health research funding disparities.

Psychedelic drug reform is not occurring at the expense of other drug reforms. Instead, it paves the way for larger reforms.

The lack of diversity among research participants can have significant consequences on generalizability and distribution of treatments.

The field has a frustrating tendency to make lofty claims about psychedelics that stray from the realities and limitations of the data.

As a scholar of religion who cares deeply about this psychedelic renaissance, I offer two points of caution from the perspective of my field.

Amid a fractured political landscape, a pandemic, and a reckoning with the country’s racist past, psychedelics may offer some hope for healing.

While city-wide decriminalization efforts make psilocybin a “low priority” for law enforcement, state and federal agencies provide no such guarantees.

A focus on furthering neurodiversity could allow the psychedelics decriminalization movement to gain broader public support.
